Acquired Company

Impel’s assets were sold to JN Bidco LLC on February 12, 2024, pursuant to an asset purchase agreement as part of Impel’s Chapter 11 liquidation, with Impel to be dissolved under the liquidation plan.

Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease. Show more

Location: 201 ELLIOTT AVE. W, SUITE 260, Washington, 98119, US | Website: impelnp.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$N/A

Open

$N/A

Volume

N/A

Day Range

$N/A - $N/A

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

0.52%

Institutional Own.

71.62%

Qtr Updated

06/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TRUDHESA (Dihydroergotamine Mesylate) Details Migraines	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INP107 (Levodopa/Carbidopa) Details Morning OFF Episodes in Parkinson’s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INP105 (Olanzapine) Details Agitation	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.